Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Stud
SOUTH SAN FRANCISCO, Calif. , May 30 /Businesswire/ - Vistagen's late-breaking poster presentation at ASCP 2023 Annual Meeting highlights long-term, open-label treatment data of as-needed intranasal administrations of fasedienol (PH94B) in real-world setting.